The PDK/PDC-Lactate Axis: A Central Hub Intersecting Cancer Metabolism and Immunosuppression.

Aberrant glucose metabolism is a hallmark of cancer metabolic reprogramming. The mitochondrial pyruvate dehydrogenase complex (PDC) acts as a central metabolic node that converts pyruvate into acetyl-CoA to sustain oxidative phosphorylation (OXPHOS). In tumor cells, however, overexpressed pyruvate dehydrogenase kinases (PDKs) phosphorylate and inactivate PDC, diverting carbon flux toward glycolysis and driving excessive lactate accumulation. Cumulative evidence demonstrates that microenvironmental lactate not only fuels tumor growth but also reshapes the tumor microenvironment (TME) into an immunosuppressive state that facilitates immune evasion. Conversely, pharmacological PDK inhibition effectively reverses this metabolic shift, depletes intratumoral lactate, restores mitochondrial pyruvate oxidation, and triggers tumor-selective apoptosis. Given these oncogenic and immunosuppressive functions, the PDC/PDK-lactate axis has emerged as a promising therapeutic target, prompting intensive research into the development of small-molecule PDK inhibitors. Here, we critically evaluate the evidence establishing this axis as a key driver of immune evasion. Unlike previous reviews that focused separately on metabolic or immunological aspects, this review uniquely integrates three emerging layers: (i) the isoform-selective functions of PDK1-4 in tumor metabolism and immune modulation; (ii) recently identified histone and non-histone lactylation as a direct epigenetic bridge connecting PDK activity to immune suppression; and (iii) a critical reappraisal of PDK inhibitors, with particular emphasis on the distinction between preclinical efficacy and clinical translation. Finally, we propose that isoform-selective targeting of PDK1 and PDK3, rather than pan-PDK inhibition, combined with immune checkpoint blockade, represents a promising strategy to overcome current therapeutic bottlenecks.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-12
DOI
https://doi.org/10.1093/carcin/bgag084
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The PDK/PDC-Lactate Axis: A Central Hub Intersecting Cancer Metabolism and Immunosuppression.

Shuxian Liao, Luting Zeng, Ruilei Huang, Yiyang Li et al.
PubMed
Cancer, Hypoxia, and Metabolism
article

The PDK/PDC-Lactate Axis: A Central Hub Intersecting Cancer Metabolism and Immunosuppression.

Shuxian Liao, Luting Zeng, Ruilei Huang, Yiyang Li, Qian Ning, Yi Yi, Jiaqi Wang, Xuhong Zhao, Yuan Gao, Shengsong Tang
article en

Abstract

Aberrant glucose metabolism is a hallmark of cancer metabolic reprogramming. The mitochondrial pyruvate dehydrogenase complex (PDC) acts as a central metabolic node that converts pyruvate into acetyl-CoA to sustain oxidative phosphorylation (OXPHOS). In tumor cells, however, overexpressed pyruvate dehydrogenase kinases (PDKs) phosphorylate and inactivate PDC, diverting carbon flux toward glycolysis and driving excessive lactate accumulation. Cumulative evidence demonstrates that microenvironmental lactate not only fuels tumor growth but also reshapes the tumor microenvironment (TME) into an immunosuppressive state that facilitates immune evasion. Conversely, pharmacological PDK inhibition effectively reverses this metabolic shift, depletes intratumoral lactate, restores mitochondrial pyruvate oxidation, and triggers tumor-selective apoptosis. Given these oncogenic and immunosuppressive functions, the PDC/PDK-lactate axis has emerged as a promising therapeutic target, prompting intensive research into the development of small-molecule PDK inhibitors. Here, we critically evaluate the evidence establishing this axis as a key driver of immune evasion. Unlike previous reviews that focused separately on metabolic or immunological aspects, this review uniquely integrates three emerging layers: (i) the isoform-selective functions of PDK1-4 in tumor metabolism and immune modulation; (ii) recently identified histone and non-histone lactylation as a direct epigenetic bridge connecting PDK activity to immune suppression; and (iii) a critical reappraisal of PDK inhibitors, with particular emphasis on the distinction between preclinical efficacy and clinical translation. Finally, we propose that isoform-selective targeting of PDK1 and PDK3, rather than pan-PDK inhibition, combined with immune checkpoint blockade, represents a promising strategy to overcome current therapeutic bottlenecks.

PubMed
Hunan University (CN), Ningxia Medical University (CN), Hunan University of Medicine (CN), Hunan Agricultural University (CN)
Good health and well-being
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon